Literature DB >> 23856618

Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease.

Rafaelle Christine Gomes Fares1, Juliana de Assis Silva Gomes, Luciana Ribeiro Garzoni, Mariana Caldas Waghabi, Roberto Magalhães Saraiva, Nayara Ingrid Medeiros, Roberta Oliveira-Prado, Luiz Henrique Conde Sangenis, Mayara da Costa Chambela, Fernanda Fortes de Araújo, Andréa Teixeira-Carvalho, Marcos Paulo Damásio, Vanessa Azevedo Valente, Karine Silvestre Ferreira, Giovane Rodrigo Sousa, Manoel Otávio da Costa Rocha, Rodrigo Correa-Oliveira.   

Abstract

Dilated chronic cardiomyopathy (DCC) from Chagas disease is associated with myocardial remodeling and interstitial fibrosis, resulting in extracellular matrix (ECM) changes. In this study, we characterized for the first time the serum matrix metalloproteinase 2 (MMP-2) and MMP-9 levels, as well as their main cell sources in peripheral blood mononuclear cells from patients presenting with the indeterminate (IND) or cardiac (CARD) clinical form of Chagas disease. Our results showed that serum levels of MMP-9 are associated with the severity of Chagas disease. The analysis of MMP production by T lymphocytes showed that CD8(+) T cells are the main mononuclear leukocyte source of both MMP-2 and MMP-9 molecules. Using a new 3-dimensional model of fibrosis, we observed that sera from patients with Chagas disease induced an increase in the extracellular matrix components in cardiac spheroids. Furthermore, MMP-2 and MMP-9 showed different correlations with matrix proteins and inflammatory cytokines in patients with Chagas disease. Our results suggest that MMP-2 and MMP-9 show distinct activities in Chagas disease pathogenesis. While MMP-9 seems to be involved in the inflammation and cardiac remodeling of Chagas disease, MMP-2 does not correlate with inflammatory molecules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856618      PMCID: PMC3811750          DOI: 10.1128/IAI.00153-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Authors:  S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

Review 2.  Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.

Authors:  Davy Vanhoutte; Mark Schellings; Yigal Pinto; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2005-12-19       Impact factor: 10.787

Review 3.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

4.  Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients.

Authors:  Qiu Jing Chen; Lin Lu; Wen Hui Peng; Jian Hu; Xiao Xiang Yan; Ling Jie Wang; Qi Zhang; Rui Yan Zhang; Wei Feng Shen
Journal:  Clin Chim Acta       Date:  2009-04-16       Impact factor: 3.786

5.  Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.

Authors:  Juliana A S Gomes; Lilian M G Bahia-Oliveira; Manoel Otávio C Rocha; Solange C U Busek; Mauro M Teixeira; João Santana Silva; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 6.  Circulating matrix metalloproteinases and their inhibitors in hypertension.

Authors:  Vanessa Fontana; Pamela S Silva; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Clin Chim Acta       Date:  2012-01-08       Impact factor: 3.786

Review 7.  Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections.

Authors:  Nathalie Geurts; Ghislain Opdenakker; Philippe E Van den Steen
Journal:  Pharmacol Ther       Date:  2011-11-28       Impact factor: 12.310

Review 8.  Clinical management of chronic Chagas cardiomyopathy.

Authors:  Manoel O C Rocha; Antonio Luiz P Ribeiro; Mauro M Teixeira
Journal:  Front Biosci       Date:  2003-01-01

9.  Characterization of CD4⁺ cytotoxic lymphocytes and apoptosis markers induced by Trypanossoma cruzi infection.

Authors:  T S L Keesen; J A S Gomes; R C G Fares; F F de Araújo; K S Ferreira; A T Chaves; M O C Rocha; R Correa-Oliveira
Journal:  Scand J Immunol       Date:  2012-09       Impact factor: 3.487

10.  Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease.

Authors:  Paulo E A Souza; Manoel O C Rocha; Cristiane A S Menezes; Janete S Coelho; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

View more
  25 in total

1.  Human amniotic mesenchymal stem cells alleviate lung injury induced by ischemia and reperfusion after cardiopulmonary bypass in dogs.

Authors:  Yong Qiang; Guiyou Liang; Limei Yu
Journal:  Lab Invest       Date:  2016-02-29       Impact factor: 5.662

2.  Circulating serum markers and QRS scar score in Chagas cardiomyopathy.

Authors:  Eva H Clark; Morgan A Marks; Robert H Gilman; Antonio B Fernandez; Thomas C Crawford; Aaron M Samuels; Alicia I Hidron; Gerson Galdos-Cardenas; Gilberto Silvio Menacho-Mendez; Ricardo W Bozo-Gutierrez; Diana L Martin; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2014-11-10       Impact factor: 2.345

3.  Matrix metalloproteinase-13 mediated degradation of hyaluronic acid-based matrices orchestrates stem cell engraftment through vascular integration.

Authors:  Amit K Jha; Kevin M Tharp; Shane Browne; Jianqin Ye; Andreas Stahl; Yerem Yeghiazarians; Kevin E Healy
Journal:  Biomaterials       Date:  2016-03-03       Impact factor: 12.479

4.  Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.

Authors:  Shivali Gupta; Trevor S Silva; Jessica E Osizugbo; Laura Tucker; Heidi M Spratt; Nisha J Garg
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

Review 5.  Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.

Authors:  Alec S T Smith; Jesse Macadangdang; Winnie Leung; Michael A Laflamme; Deok-Ho Kim
Journal:  Biotechnol Adv       Date:  2016-12-20       Impact factor: 14.227

6.  Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.

Authors:  Daniel Musikant; Romina Higa; Cristina E Rodríguez; Martin M Edreira; Oscar Campetella; Alicia Jawerbaum; María S Leguizamón
Journal:  Biochimie       Date:  2021-04-20       Impact factor: 4.079

7.  Matrix Metalloproteinase-2 (MMP-2) Gene Deletion Enhances MMP-9 Activity, Impairs PARP-1 Degradation, and Exacerbates Hepatic Ischemia and Reperfusion Injury in Mice.

Authors:  Hiroyuki Kato; Sergio Duarte; Daniel Liu; Ronald W Busuttil; Ana J Coito
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

8.  Molecular mechanisms behind progressing chronic inflammatory dilated cardiomyopathy.

Authors:  Daiva Bironaite; Dainius Daunoravicius; Julius Bogomolovas; Sigitas Cibiras; Dalius Vitkus; Edvardas Zurauskas; Ieva Zasytyte; Kestutis Rucinskas; Siegfried Labeit; Algirdas Venalis; Virginija Grabauskiene
Journal:  BMC Cardiovasc Disord       Date:  2015-03-26       Impact factor: 2.298

9.  Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia.

Authors:  Emi E Okamoto; Jacqueline E Sherbuk; Eva H Clark; Morgan A Marks; Omar Gandarilla; Gerson Galdos-Cardenas; Angel Vasquez-Villar; Jeong Choi; Thomas C Crawford; Rose Q Do; Rose Q; Antonio B Fernandez; Rony Colanzi; Jorge Luis Flores-Franco; Robert H Gilman; Caryn Bern
Journal:  PLoS Negl Trop Dis       Date:  2014-10-02

Review 10.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.